)
)
)
Epsilogen Ltd
Epsilogen is the world’s leading pan-isotype antibody therapeutic company for the treatment of cancer
Our unique and proprietary expertise is focused on the discovery and development of immunoglobulin IgE, IgA and IgG-based therapeutics. The immune system relies upon the differential effector functions of the various antibody isotypes to generate the best immune response to a given challenge. Similarly, we match the attributes of each isotype to a given cancer to optimize performance. We have also combined different isotypes into single antibody molecules to broaden and strengthen their anti-cancer potential.
Our lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic. It targets folate receptor ⍺ and was found to be safe and well tolerated in a phase I study with early signs of clinical activity. A phase Ib study in platinum-resistant ovarian cancer patients is now underway.
Address
LondonUnited Kingdom
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)